Flputnam Investment Management Co. Sells 1,977 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Flputnam Investment Management Co. trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 50.2% during the fourth quarter, Holdings Channel reports. The fund owned 1,962 shares of the medical research company’s stock after selling 1,977 shares during the quarter. Flputnam Investment Management Co.’s holdings in Charles River Laboratories International were worth $362,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Empirical Finance LLC raised its position in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares during the period. Fiduciary Financial Group LLC grew its stake in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after buying an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. M&T Bank Corp lifted its position in Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after acquiring an additional 66 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after acquiring an additional 95 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $163.62 on Tuesday. The firm has a market cap of $8.37 billion, a P/E ratio of 1,090.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The firm’s 50-day simple moving average is $170.50 and its 200-day simple moving average is $186.58. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the business earned $2.46 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).